<aside> ⚠️ Problem:
Today, doctors and researchers see only a fraction of the immune signals that shape cancer progression and treatment.
Most of this critical information is lost with current lab methods — making therapy decisions slower, riskier, and less precise.
</aside>
<aside> 💡 Solution:
ImmunoEdge captures the full set of immune targets directly from tiny biopsy samples using a novel miniaturized technology.
This gives oncologists a clear map of the disease landscape — helping them identify the right therapeutic targets and act faster.
</aside>
<aside> 📈 Business Model:
ImmunoEdge delivers immune target discovery and analysis as a service to research centers, biotech companies, and hospitals.
We also license our patented technology to scale its impact in diagnostics and personalized oncology.
</aside>
<aside>
Mogjib Salek, PhD
Founder & Managing Director
</aside>
<aside>
Jalal Vakili, MD, PhD
Strategy & Commercial Lead
</aside>
<aside> 💌 Questions? Feel free to reach out to us:
</aside>